In an earlier study, we showed significant increases in the time to treatment failure (TTF) and ORR for HER2-negative ABC and identified a patient subgroup in which OS benefited from PB therapy through propensity score matching6. The gene discussed is ERBB2; the disease is aneurysmal bone cyst.